This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
The Best Cheap Stocks Under $10 to Buy in December and 2026
by Benjamin Rains
Today, we explore how investors can find the best-in-class cheap stocks trading for under $10 a share to buy now.
FOLDNegative Net Change
biotechs
KYMR Stock Surges on Upbeat Data From KT-621 Atopic Dermatitis Study
by Zacks Equity Research
Kymera jumps after phase Ib study data show KT-621 delivers strong STAT6 degradation and broad clinical activity in patients with atopic dermatitis.
SNYNegative Net Change ANIPPositive Net Change CSTLPositive Net Change KYMRNegative Net Change
biotechs
Agios Awaits Pyrukynd Decision in Thalassemia as FDA Misses Due Date
by Zacks Equity Research
AGIO faces uncertainty as the FDA misses its Dec. 7 deadline related to the sNDA for Pyrukynd in thalassemia and offers no new timeline.
AGIONegative Net Change ANIPPositive Net Change CRMDPositive Net Change CSTLPositive Net Change
biotechs
GPCR Stock Soars 102% on Strong Phase II Obesity Data for Aleniglipron
by Zacks Equity Research
Structure Therapeutics jumps after phase II data show aleniglipron delivering strong, durable weight-loss results across multiple studies.
NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Will Cobenfy Become a Growth Driver for BMY's Neuroscience Business?
by Ekta Bagri
Bristol Myers Squibb moves forward with its ADEPT-2 study on Cobenfy, delaying data to next year but boosting investor sentiment.
BIIBNegative Net Change BMYNegative Net Change LLYNegative Net Change
biotechnology biotechs medical pharmaceuticals
PRAX Stock Skyrockets 520% in 3 Months: Here's What You Need to Know
by Zacks Equity Research
Praxis stock soars after late-stage data show strong efficacy for ulixacaltamide therapy in essential tremor and momentum builds toward an early-2026 regulatory filing.
ANIPPositive Net Change CRMDPositive Net Change ARQTNegative Net Change PRAXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Incyte's Rare Blood Cancer Therapy Gets FDA's Breakthrough Status
by Zacks Equity Research
INCY secures FDA Breakthrough Therapy status for INCA033989 after early data show rapid and sustained platelet normalization in essential thrombocythemia patients.
INCYNegative Net Change ANIPPositive Net Change CRMDPositive Net Change ARQTNegative Net Change
biotechnology biotechs medical pharmaceuticals
ABSI Stock Up on Initiating Dosing in Androgenetic Alopecia Study
by Zacks Equity Research
Absci Corporation stock jumps after initiating dosing in its phase I/IIa ABS-201 study for androgenetic alopecia, seeking early safety and efficacy signals.
ANIPPositive Net Change CRMDPositive Net Change ARQTNegative Net Change ABSIPositive Net Change
biotechnology biotechs medical pharmaceuticals
CAPR Stock Skyrockets 282% in a Week: Here's What You Need to Know
by Zacks Equity Research
Capricor Therapeutics stock soars after meeting key goals with statistical significance in a phase III study of deramiocel for Duchenne cardiomyopathy.
ANIPPositive Net Change CRMDPositive Net Change CAPRNegative Net Change ARQTNegative Net Change
biotechnology biotechs medical pharmaceuticals
Biotech ETF (XBI) Hits New 52-Week High
by Zacks Equity Research
XBI hits a 52-week high, climbing 85% from its low, as biotech gains momentum from AI adoption and favorable market trends.
XBINegative Net Change
biotechs etfs
Can Galafold Continue to Drive Amicus' Top Line in 2026?
by Kanishka Das
FOLD leans on rising Galafold sales on the back of strong commercial execution as momentum builds into 2026.
SNYNegative Net Change TEVAPositive Net Change FOLDNegative Net Change
biotechs
Denali Enters Into a $275M Funding Deal With Royalty Pharma
by Ekta Bagri
DNLI secures a $275M funding deal with Royalty Pharma tied to potential approvals for its Hunter syndrome therapy.
BIIBNegative Net Change RPRXNegative Net Change DNLINegative Net Change TAKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Will Breyanzi's Label Expansion Boost BMY's CAR T Cell Therapy Sales?
by Ekta Bagri
Bristol Myers gains FDA approval to expand Breyanzi's label to R/R marginal zone lymphoma, strengthening its CAR T portfolio amid rising sales.
NVSPositive Net Change BMYNegative Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can DefenCath Continue to Aid CorMedix's Long-Term Growth Ahead?
by Kanishka Das
CRMD's lead product, DefenCath, generates $167.6M in sales in the first nine months of 2025, with market exclusivity through 2033 likely to provide growth momentum.
PFENegative Net Change AMPHNegative Net Change CRMDPositive Net Change
biotechs
Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals
by Zacks Equity Research
PHVS shares jump as deucrictibant delivers rapid symptom relief in RAPIDe-3, boosting momentum toward a planned 2026 regulatory filing.
BCRXNegative Net Change IONSNegative Net Change KALVNegative Net Change PHVSNegative Net Change
biotechs medical
BMY Gains on News of Continuation of Alzheimer's Disease Study
by Zacks Equity Research
Bristol Myers jumps after choosing to continue its phase III ADEPT-2 study on Cobenfy for Alzheimer-related psychosis, delaying data to next year.
BMYNegative Net Change FOLDNegative Net Change ANIPPositive Net Change CRMDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Zoetis Stock Plummets 24.8% YTD: Here's What You Need to Know
by Zacks Equity Research
ZTS faces steep YTD losses as safety concerns hit key osteoarthritis therapies, forcing revenue cuts while new approvals aim to stabilize growth.
ZTSNegative Net Change CRMDPositive Net Change ADMAPositive Net Change ARQTNegative Net Change
biotechnology biotechs medical pharmaceuticals
How Strong Is AbbVie's Immunology Franchise After Humira's LOE?
by Sundeep Ganoria
ABBV rebounds after Humira's LOE as soaring Skyrizi and Rinvoq sales drive a powerful immunology comeback.
JNJNegative Net Change LLYNegative Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals
Bayer Stock Up as Government Backs Supreme Court Review in Roundup Case
by Zacks Equity Research
Bayer shares jump after the U.S. Solicitor General backs a Supreme Court review of its Roundup case, adding momentum to its strong 2025 run.
JNJNegative Net Change BAYRYPositive Net Change ANIPPositive Net Change CRMDPositive Net Change
biotechnology biotechs medical pharmaceuticals
PCRX's Iovera Outperforms RFA Therapy in Pilot Study for Low Back Pain
by Zacks Equity Research
Pacira BioSciences' iovera shows stronger, longer-lasting relief than RFA in a pilot CLBP study, highlighting its tissue-sparing approach and potential spine-care impact.
PCRXPositive Net Change CRMDPositive Net Change ADMAPositive Net Change ARQTNegative Net Change
biotechnology biotechs medical pharmaceuticals
AZN's Baxdrostat Gets FDA Priority Tag for Uncontrolled Hypertension
by Zacks Equity Research
AstraZeneca's NDA for baxdrostat gains FDA priority review for treating hard-to-control hypertension. A decision is due in the second quarter of 2026.
AZNNegative Net Change CRMDPositive Net Change ADMAPositive Net Change ARQTNegative Net Change
biotechs
Can LLY Strengthen Its Lead as GLP-1 Price Cuts Reshape the Market?
by Ahan Chakraborty
Eli Lilly cuts Zepbound prices, igniting a fierce battle with Novo Nordisk to expand access and defend share in the obesity market.
NVONegative Net Change LLYNegative Net Change AMGNNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Vertex Up 9.2% in 3 Months: Should You Buy, Sell or Hold the Stock?
by Kinjel Shah
VRTX rises 9.2% in three months but trails its industry as mixed new-drug sales and tightened 2025 guidance cloud near-term momentum.
VRTXNegative Net Change MRNAPositive Net Change CRSPNegative Net Change
biotechs pharmaceuticals
REGN & Tessera Collaborate to Develop Gene-Editing Therapy for AATD
by Zacks Equity Research
Regeneron teams up with Tessera to advance TSRA-196, aiming to correct the genetic cause of AATD as preclinical data support its move toward trials.
REGNNegative Net Change RHHBYNegative Net Change ANIPPositive Net Change CRMDPositive Net Change
biotechnology biotechs medical pharmaceuticals
BHC Stock Up as Solta Acquires Shibo's Aesthetics Distribution Business
by Zacks Equity Research
BHC jumps 11% as Solta Medical acquires Wuhan Shibo Zhenmei, gaining full control of its China aesthetics distribution business.
FOLDNegative Net Change ANIPPositive Net Change CRMDPositive Net Change BHCNegative Net Change
biotechnology biotechs medical pharmaceuticals